Gastrointestinal tumors remain a global health challenge, with high incidence and mortality. Among them, colorectal cancer (CRC) carries the heaviest burden and serves as a key model for how the gut ...

Intestinal stem cells help regenerate the lining of the intestine, and that lining or epithelium plays a number of critical roles in digestion, nutrient absorption, and immunity. Scientists have now ...

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...

Scientists have made a breakthrough in the hunt for a new vaccine for killer hospital bug Clostridioides difficile (C. diff). Scientists have made a breakthrough in the hunt for a new vaccine for ...

A study funded by the National Institutes of Health found that Glucosyltransferase domain is a possible molecular target for therapeutic interventions for Clostridioides difficile infection.

A new study paves the way for the development of next generation therapeutics for the prevention and treatment of Clostridioides difficile infection (CDI), the most frequent cause of ...

A University of California, Irvine-led study suggests that the glucosyltransferase domain (GTD) is an ideal molecular target for therapeutic interventions for Clostridioides difficile infection (CDI).

Clostridium bacteria, computer illustration. Clostridia are spore-forming bacteria that include several human pathogenic species, C. difficile, C. tetani, C. botulinum, C. perfringens, and others. C.

The Upstate Institute for Global Health is looking for over 1000 Central New Yorkers to participate in its largest clinical trial, testing a possible vaccine to prevent "C. diff." ...

Scientists have made a breakthrough in the hunt for a new vaccine for killer hospital bug Clostridioides difficile (C. diff). University of Exeter researchers first identified a gene in C. diff ...